Sam Chun Dang Pharm disclosed that it signed an exclusive Japan distribution and supply agreement with Daiichi Sankyo Espha Co., Ltd. for an age-related macular degeneration biosimilar, SCD411, on November 2, 2026.

Sam Chun Dang Pharm disclosed that on November 2, 2026 it signed an exclusive Japan distribution and supply agreement for SCD411 with Japan's Daiichi Sankyo Espha Co., Ltd. The specific upfront payment, milestone amounts and profit-sharing ratio were not disclosed at the counterparty's request to keep business information confidential. The company said milestone payments received at each stage, including the upfront payment, are not refundable, and that the agreement may be terminated if the counterparty commits a material breach or becomes bankrupt.

1. 01

   The upfront payment, total milestone amount and profit-sharing ratio were not disclosed due to confidentiality obligations under the agreement.

2. 02

   The company said it holds the Japanese marketing authorization for SCD411 in its own name under the foreign special approval system, and that the counterparty, as a designated marketing authorization holder (D-MAH), handles sales in Japan and maintenance of the authorization.

3. 03

   The company said it had agreed to terminate its prior exclusive Japan distribution and supply agreement for SCD411 with SENJU Pharmaceutical Co., Ltd. of Japan before entering into this agreement.

4. 04

   The company said some of the milestones are conditional on the start of product sales, and that profit-sharing revenue depends on actual sales performance and is not a fixed amount.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Counterparty

Daiichi Sankyo Espha Co., Ltd. (Japan)

Product covered

SCD411 (aflibercept biosimilar, 2mg prefilled syringe and vial)

Supply period

From the signing date until 10 years after product launch, renewing automatically in 2-year increments

Signing date (date of occurrence)

November 2, 2026

Disclosure deferral deadline

November 2, 2036

Filing facts

Filing type

Supply Contract

Report name

Material Management Information for Investment Decisions

Filed

Nov 2, 2026

Receipt number

20261102900634